Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 ...

CEPI is providing US$4.5 million to non-profit Fondazione Biotecnopolo di Siena (FBS) for proof-of-concept research that will explore whether producing antigens in C1 filamentous fungus—applying ...

JUPITER, Fla., March 20, 2025 (GLOBE NEWSWIRE) -- (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of ...